1 Title: Locus-specific stratification and prioritization unveil high risk genes

2 underlying hyperuricemia

- 3 Authors: Jing Zhang^{1,2}, Yue Guo^{1,2}, Luyu Gong^{1,2}, Limei Xia^{1,2}, Qiaoqiao Liu^{1,2},
- Kangchun Wang^{1,2}, Qi Wang^{1,2}, Zhaojun Liu^{1,2}, Zhaohui Qin³, Shaolin Shi^{4*}, Jingping
 Yang^{1,2,4*}
- 6
- ⁷ ¹State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing
- 8 University, Nanjing, Jiangsu, 210093, China.
- ⁹ ²Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University,
- 10 Nanjing, Jiangsu, 210093, China.
- ¹¹ ³Department of Biostatistics and Bioinformatics, Rollins School of Public Health,
- 12 Emory University, Atlanta, GA, 30322, USA.
- 13 ⁴National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated
- 14 Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, 210093, China.
- 15 * Corresponding author. Email: shaolinshi1001@yahoo.com; jpyang@nju.edu.cn.

17 Abstract

18 The development of alternative medications for urate-lowering therapies is imperative 19 for patients that are intolerant to current treatments. Despite GWAS have identified 20 hundreds of loci associated with serum urate levels, the mechanistic understanding and 21discovery of drug targets remain difficult. This difficulty arises from the multiple-22 independent-associations challenge in the genomic studies of complex diseases as 23 hyperuricemia. Here, we introduced a locus-specific stratification (LSS) and gene 24 regulatory prioritization score (GRPS) approach to address the multiple-independent-25associations challenge. By integrating with kidney single-cell chromatin accessibility 26 and gene expression, LSS identified functional SNPs, regulatory elements, and genes 27for 118 loci. The interpretability was increased by 1.4 to 5.2 fold. GRPS prioritized 28 genes and nominated under-explored drug target with high confidence, which was 29 validated using CRISPR activation and phenotypic assays. Our findings not only 30 identified top causal genes but also proposed the regulatory mechanisms for pathogenic 31 genes, expanding our knowledge of the genetic contribution in complex diseases as 32 hyperuricemia.

33 **One-sentence summary**

A novel approach to comprehensively explore genetic contribution and nominate
 reliable causal genes for complex diseases as hyperuricemia.

36

37 Introduction

38 Hyperuricemia, characterized by elevated serum urate levels, is a complex disease affecting various complications (1-3). Although the dominant narrative about 39 40 hyperuricemia has focused on dietary, recent research suggests that diet plays only a 41 limited role in regulation of serum urate in the healthy population (4). Instead, it has 42 been estimated that genetic contribution for hyperuricemia ranges from 40% to 73% 43 (5). There are currently urate-lowering therapies developed based on genetic targets, 44 such as allopurinol, which inhibits xanthine oxidase and the production of urate, and 45 benzbromarone, which inhibits URAT1 and reabsorption of urate in kidney. However, 46 these medications caused hypersensitivity syndrome, hepatotoxicity or other adverse 47 effects in specific patient populations (6). Therefore, it is necessary to further nominate 48 disease-associated genes or drug targets in order to develop medications for intolerant 49 populations. Large-scale genome-wide association studies (GWAS) have identified 50 over 200 loci associated with serum urate levels (7, 8), but mechanistic understanding 51of the causal variants and genes underlying these loci remains partially explored, 52limiting the translation of genetic result to alternative medications.

53 For complex diseases, the presence of multiple independent associations at 54 disease-associated locus is commonly observed (9-12). For example, four regions at SLC2A9 locus have significant causal effects on serum urate levels (13). However, due 55 56 to limitation of computational burden, the most commonly used methods for identifying 57 causal variants, such as lead SNP extension by linkage disequilibrium (LD), genetic 58 and epigenetic fine mapping, or colocalization (14-17), assume exactly one causal 59 variant per locus (18, 19). As all the independent disease associations could contribute 60 to gene regulation and trait association at the locus, these above methods may not fully 61 map causal variants and leave a large number of loci mechanistically unresolved. 62 Recent studies have performed the colocalization analysis of urate-associated loci with 63 kidney expression quantitative trait loci (eQTLs), but the result could only characterize 64 risk for tens loci and did not find the well-known targets in kidney including SLC22A12

65 (encoding URAT1) and *SLC2A9* (encoding GLUT9) (7, 20). Therefore, it is urgent to
66 find an effective way to overcome the issue of multiple independent associations in
67 complex diseases and comprehensively understand the mechanism of genetic
68 contribution.

69 The multiple independent associations in complex diseases also accompany the 70 complexity of gene regulation at disease-associated locus, and hinder gene 71prioritization. Previous studies have shown that drug targets with genetic supports are 72 more likely to be therapeutically valid (21, 22), but drug target discovery in complex 73 diseases remains challenging. The heritability of complex diseases could be explained 74by the cumulative effects of many variants (23), which are mainly located in non-coding 75 regions and regulate gene expression in a cell-type-specific manner (24, 25). Thus, 76 cumulative-regulation-based methods to prioritize the candidate genes is expected to 77 nominate the most probable causal genes and potential drug targets. Recent regulation-78 based methods have leveraged the causal gene nomination, but they are not developed 79 for complex diseases and have certain limitations. ABC-Max only assigned one variant-80 gene pair with the strongest regulatory score (26), but overlooked the complex 81 regulation between variants and genes (24). Open Targets Genetics and H-MAGMA 82 took into account all the variant-gene connectivity, but the connectivity is considered 83 qualitatively rather than quantitatively (27, 28). The incompleteness of cumulative 84 regulation maps, together with incomplete variant coverage and the limited cell type 85 resolution, hinder the prioritization of causal genes. Thus, a method that systematically 86 and accurately considers the cumulative regulation is required for prioritizing genes for 87 complex disease.

In the current study, we propose a novel approach with locus-specific stratification and prioritization to comprehensively explore genetic contribution in complex diseases and nominate reliable disease-associated genes. Locus-specific stratification (LSS) efficiently extract all high-risk variants in addition to lead SNP based on a locusspecific background and overcome the challenge of multiple-independent-associations

93 in complex diseases. To prioritize genes, we develop gene regulatory prioritization 94 score (GRPS) to evaluate cumulative regulation on genes by integration high-risk variants from LSS with scATAC-seq and scRNA-seq datasets. Using this strategy, we 95 96 efficiently resolved genetic risk mechanism for 118 out of 267 loci, and nominated 97 more reliable gene targets for hyperuricemia. We further validated the regulatory 98 potential of resolved high-risk variant on candidate causal gene by CRISPR activation 99 (CRISPRa), and evaluated the effect of top prioritized gene on cellular urate level. Our 100 study established a computational efficient method for GWAS interpretation of 101 complex disease, extended genetic mechanistic understanding of hyperuricemia, and 102 ultimately prioritizing genes with high confidence.

103 **Results**

104 Locus-specific stratification leverages interpretability of loci with multiple 105 independent-associations

106 The GWAS of serum urate level exhibited overwhelming multiple-independent-107 associations challenge. For the available GWAS results of serum urate level, 108 independent association analysis revealed 22 to 128 loci with multiple independent 109 associations, ranging from 69.95%-95.65% of all the loci (Fig. 1A). For instance, at 110 locus chr4:9,743,616-10,243,616 with lead SNP rs3775947, in addition to lead SNP 111 and SNPs within its high LD neighborhood, there were also numerous variants showing 112 extremely strong trait association with -log10(p-value) even over 1000 (Fig. 1B). This 113 suggested that such a locus may not be fully explained by only one association. Notably, 114 at such highly associated locus, the locus-specific background is much higher than 115genome-wide background, suggesting a one-size-fits-all cutoff might not be appropriate.

116 We observed that the distribution of significancy at locus with multiple-117 associations tended to be reversed "L" shape with a plateau. The plateau was consisted 118 of numerous high-risk associations, and generally harbored the top quantile 119 associations (Fig. 1C and Fig. S1). In order to efficiently and comprehensively explore 120 the genetic contribution, we proposed the LSS strategy to extract all high-risk 121 associations based on locus-specific background. We ranked the variants by descending 122 significance of variant-trait associations within each locus and took the top quartile 123 associations as rank 1 for further analysis (Fig. 1D). LSS captured the multiple 124 independent associations (Fig. 1E and Fig. S1) without bringing in noise at locus with 125single association (Fig. 1F and Fig. S2).

Previous studies highlighted that disease-associated variants enriched at tissue and cell type specific regulatory regions (29-31). We thus identified the target tissue and generated tissue specific single cell EpiMap to pinpoint the potential causal variants of

129 these high-risk associations. By LD regression, we found the regulatory contribution 130 from kidney tissue is highest (Fig. S3). We then focused on the regulatory mechanism 131 in kidney. We generated cell type EpiMap with our previously generated kidney 132 scATAC-seq data and integrated it with the rank 1 associations (Fig. 1D). The results 133 showed that our strategy could explain genomic function for 220 out of 267 loci from 134 the three studies (Table S1). When compared with other methods including high LD 135extension, Bayesian fine-mapping and colocalization, we found LSS could improve the 136 interpretability of GWAS loci by 8.13% to 69.92% (Fig. 1G). Furthermore, we 137 examined the contribution of these functional high-risk variants, and found that the 138 variants identified by LSS contributed more highly and specifically to gout, the most 139 common complication of hyperuricemia (Fig. 1H). These results suggested that LSS 140 could pinpoint the functional high-risk variants for complex diseases more 141 comprehensively and specifically.

142 LSS identified variants revealed cell-type-specific contribution on complex disease

143 We further examined the cell types in which the identified high-risk variants could 144 play a role in. The result showed that 77.86% of these high-risk variants exhibited 145 chromatin accessibility in proximal tubular cells, and this fraction was followed by that 146 in distal tubular cell types (Fig. 2A). The result is consistent with fact that urate 147 homeostasis is maintained mainly through excretion by kidney tubules (20). We also 148 found that 48.12% of the variants located in regions only accessible in one cell type, 149 mostly in proximal tubular cells and then in distal tubules (Fig. 2B and Fig. S4). For 150 example, at the locus chr8:75,316,533-75,816,533 with lead SNP rs2941484, the lead 151SNP and its proxy SNP by LD extension showed no accessibility in any kidney cell 152type (Fig. 2C). We found by LSS that high-risk variant rs2943549, which is in an independent association over 26kb away from the lead SNP, located in a region 153 154 specifically accessible in proximal tubular cell (Fig. 2C). The phenome-wide 155association study (PheWAS) (32), which is a powerful approach to comprehensively

156 evaluate associations between genetic variants and phenotypes, revealed that rs2943549 157 has the strongest association with urate-related phenotypes among the traits (Fig. 2D). In another locus chr4:9,743,616-10,243,616 with lead SNP rs3775947, a high-risk 158 159variant rs4447862 in addition to lead SNP showed accessibility, revealing an additional 160 risk (Fig. 2E). Notably, rs4447862 demonstrated a remarkable association with uric 161 acid (Fig. 2F), yet this risk variant could not be identified by extension of the lead SNP. 162 These results suggested that high-risk variant from independent association could 163 function as genomic regulation in a cell-type-specific manner, and contribute 164 mechanistically to the genetic risk of hyperuricemia.

165 Integrated regulatory network uncovers candidate causal genes of functional 166 high-risk variants

167 Genetic lesions in non-coding regulatory elements contribute to disease by 168 modulating the causal gene expression (14). To fully explain the regulatory 169 mechanisms of the above functional high-risk variants, we integrated the scRNA-seq 170 and scATAC-seq profiles of kidney to construct the transcriptional regulatory networks 171by identifying CREs with accessibility correlated to gene expression ('peak-to-gene 172links') (Fig. 3A and Fig. S5A). Based on the regulatory network, we identified 160 173protein-coding genes linked to 232 variants in 118 loci (Table S2). Our approach 174interpreted mechanism for 1.4 to 5.2 fold more loci than the other approaches on the 175same GWAS study (Fig. 3B), and identified an additional 32 to 85 candidate genes (Fig. 176 3C).

To examine the relevance of the identified candidate causal genes from functional high-risk variants, we performed gene function analysis. The ontology and pathway enrichment revealed that the genes were mainly involved in urate and organic anion transport (Fig. S5B). Disease enrichment analysis showed that they were involved in urate measurement and gout (Fig. 3D). Notably, genes linked with LSS-only high-risk variants were also implicated in uric acid measurement (Fig. 3E and Fig. S5C). For

183 example, at the locus chr1:154,935,239-155,435,239, we found that independent high-184 risk variant rs3814316, instead of lead SNP rs2070803, functioned as a regulatory 185 element in distal tubular cell types and linked to gene MUC1 (Fig. 3F). MUC1 has been 186 shown to be important for urate level as its mutation in tubulointerstitial nephropathy 187 patients can result in clinical manifestations of gout (33). In contrast, the lead SNP 188 rs2070803 showed no regulatory capacity for kidney MUC1 expression. In consistent 189 with our finding, rs3814316 showed higher CADD score and cast even stronger eQTL 190 effect on MUC1 than rs2070803 (Fig. 3G and 3H). These results suggested that the 191 independent high-risk variant rs3814316 identified by our study was more likely to be 192 the causal variant for disease association at the *MUC1* locus. Our findings have not only 193 identified candidate causal genes for disease-associated loci, but have also proposed the 194 more plausible regulatory mechanisms for pathogenic genes. Taken together, LSS is a computational efficient method to deal with multiple-independent-association 195 196 challenge of complex disease, and could better explore the mechanism of complex 197 diseases.

198 Comprehensive prioritization score nominates potential drug target genes

199 As there are independent high-risk variants identified by LSS, there could be 200 complex regulation between variants and candidate causal genes. For urate-level 201 associated loci, we observed that 42% variants could be linked to more than one gene, 202 and 44% of the identified candidate causal genes could be regulated by more than one 203 variant (Fig. 4A and 4B). For example, SLC22A12, which encodes a known urate 204 transporter, URAT1, was regulated by up to 15 functional high-risk variants in 11 205 regulatory elements identified in this study at locus chr11: 64,315,390-64,815,390 with 206 lead SNP rs71456318 (Fig. S6). In order to nominate the most probable causal genes 207 for further targeted therapies, it is necessary to prioritize genes based on a comprehensive regulation estimation. We developed gene regulatory prioritization 208 209 score (GRPS) to take full consideration of the complexity of transcriptional regulation.

GRPS did not require any previous functional evidence, but rather evaluated pathogenic risk for genes objectively based on the risk level of causal variants linked to the gene, the regulation strength of causal variants on the gene, and the polygenic effects of multiple independent causal variants (Fig. 4C). Prioritizing all 160 candidate genes using GRPS showed that the top candidates were overwhelmingly supported by evidence for trait association from previous studies (Fig. 4D).

216 It is noteworthy that the top-ranking genes extensively enriched for known urate 217 transporters and gene targets that are already in clinical use or clinical trials (Fig. 4E). 218 SLC22A11 and SLC22A12 have been approved as confirmed drug targets for targeted 219 therapies of hyperuricemia and gout (34), and SLC2A9 and SLC17A1 have been 220 validated as potent targets for therapy in vivo (35, 36). Furthermore, the priority by 221 GRPS ranking could more thoroughly and effectively uncover putative drug targets (Fig. 4F and 4G). For example, SLC17A1 was ranked 5th in GRPS, but was positioned 222 at 42nd in Open Targets Genetics, and was even missed out in H-MAGMA or ABC-223 224 Max (Table S3).

In addition to hyperuricemia, we also applied LSS and GRPS to other complex 225 226 diseases and traits including creatinine-based estimated glomerular filtration rate 227 (eGFRcrea), blood urea nitrogen (BUN), urinary albumin-to-creatinine ratio (UACR), 228 gout and chronic kidney disease (CKD). The results showed that LSS generally 229 increased the interpretability of GWAS for complex diseases and traits with multiple 230 independent associations (Fig. S7A-D), and GRPS uncovered candidate causal genes 231 with high credibility (Fig. S7E). All these results indicated that the approach was 232 generally applicable to GWAS of complex diseases and could leverage the investigation 233 of mechanism and drug target of complex diseases.

234 SLC17A4 as top nominator promoted the cellular urate transport

235 Among the top nominated gene targets, SLC17A4 was the one that has not been 236 demonstrated to be involved in urate levels (Fig. 4E). Although it was supposed that 237 SLC17A4 encodes an organic anion transporter, its role in cellular urate transport and 238 regulatory mechanism have never been determined. At the GWAS locus 239 chr6:25,559,488-26,059,488 where SLC17A4 located, the lead SNP rs1359232 did not 240 show regulatory potential, but the additional high-risk variant rs1165183 located at a 241 regulatory region and linked with the 81 kb upstream gene SLC17A4 (Fig. 5A). 242 rs1165183-harboring-CRE was proximal tubular-specific accessible and SLC17A4 243 specifically expressed in proximal tubular cells (Fig. 5A and 5B). In order to verify the 244 regulatory potential of rs1165183-harboring-CRE on SLC17A4, we used CRISPRa 245 system (37) to activate the activity of the regulatory element (Fig. S8A). Upon 246 activation, we found that the expression of SLC17A4 was significantly up-regulated 247 (Fig. 5C).

As rs1165183 was associated with urate level with -log10(p-value) as high as 148, 248 SLC17A4 was a strong candidate gene to affect urate level. To further determine the 249 250 function of SLC17A4 on urate level, we carried out functional experimental using a 251sodium urate-induced model. We overexpressed SLC17A4 in HEK293T cells which 252 did not express SLC17A4 endogenously (Fig. 5D). We then added sodium urate and 253 monitored changes in urate levels. The results showed that overexpression of SLC17A4 254significantly changed cellular urate levels upon sodium urate overload (Fig. 5E and Fig. 255 S8B). The results confirmed that rs1165183-element could modulate the expression of 256 SLC17A4 which affected the transport of cellular urate.

257 **Discussion**

GWAS studies of serum urate levels have identified hundreds of genetic loci associated with hyperuricemia. However, multiple independent association in complex diseases complicates the deciphering of the mechanisms of these loci. Here, we proposed an integrated strategy that combined LSS and GRPS to deal with the multiple

independent associations of complex diseases. LSS improved the functional interpretability of GWAS for complex diseases. Based on the candidate causal variants and genes revealed by LSS, GRPS considered the complexity of transcriptional regulatory networks for gene prioritization, and comprehensively and accurately nominated causal genes. Our work further investigated and confirmed the regulatory mechanism and function of *SLC17A4* locus and contributed to a theoretical foundation for the development of alternative medication in the future.

269 Our research has introduced a strategy for full understanding of genetic 270 contribution in complex diseases. LSS differs from previous approaches which assume 271single association, it can efficiently and comprehensively extract high-risk variants 272 from all independent associations without increasing computational burden. It 273 significantly enhances the interpretability of GWAS results of complex diseases. For 274example, LSS facilitates identification of the causal genes SLC22A12 and SLC22A11. In contrast, the previous colocalization analysis of serum urate GWAS and kidney 275276 eQTL did not show the two genes as causal genes (7, 34). SLC22A12 and SLC22A11 277 are in the locus which is highly associated with urate levels with -log10(p-value) as 278 high as 245. URAT1 encoded by SLC22A12 is the target of benzbromarone which is an 279 well-known uricosuric drug that functions by increasing urate excretion in the kidney's 280 proximal tubule through inhibition of the dominant apical urate exchanger in the human 281 proximal tubule (38). OAT4 encoded by SLC22A11 is the target of probenecid which 282 is approved to treat gout (34). All these evidences indicated SLC22A12 and SLC22A11 283 are truly causal genes for genetic association of urate level. Additionally, our study 284 could reveal the regulatory mechanism for pathogenic genes. We identified the 285potential causal variant rs38814316 instead of the lead SNP for the regulation of MUC1, 286 revealing an unknown regulatory mode for known pathogenic genes. Thus, LSS can be 287 used to leverage the interpretation of GWAS of complex diseases and fully uncover the 288 underlying mechanisms.

289 In evaluating the pathogenicity of all candidate causal genes, the GRPS considers 290 all essential factors for the regulatory prioritization. This strategy reliably identifies the 291 causal genes for complex diseases based on their fully linked genetic regulation, 292 without the necessity of prior functional evidence. This approach is valuable for 293 uncovering the genetic underpinnings of diseases, especially when experimental data 294 for biological function may be limited or unavailable. Compared to other methods such 295 as H-MAGMA, ABC-Max and Open Targets Genetics, which do not sufficiently 296 consider the complexity of regulation at loci in complex diseases, GRPS-prioritized top 297 genes exhibited a strong association with putative drug targets. We successfully 298 identified 4 drug targets in kidney in the top rank. In addition to already known drug 299 targets and our newly proposed drug target, it is interesting that *IGF1R* is among the 300 top prioritized genes. IGF1R have been already approved as drug targets for treating 301 other diseases (34). Our finding provides a favorable condition for drug repurposing. 302 Overall, it is indicated that comprehensive integration of regulatory information 303 provides a more reliable evaluation of gene pathogenicity, and can help identify 304 promising drug target genes to facilitate drug development for treating complex 305 diseases.

306 However, a potential limitation of this study is that it focused exclusively on 307 kidney tissue that shows the highest risk for hyperuricemia. In addition to kidney tissues, 308 we did not explore other tissues involved in urate metabolism, such as the intestine and 309 liver, which may also contribute to the pathogenesis of hyperuricemia (Fig. S3). 310 Subsequent applications of our proposed strategy in other tissues may expand the 311 understanding of the pathogenesis of hyperuricemia. Importantly, this work takes an 312 important step forward by providing comprehensive functional annotation of risk loci 313 in complex diseases. We have also tested our strategy to the GWAS of other kidney 314 complex diseases or traits and demonstrated the robust applicability of our strategy and 315 its power in tackling the complexities of genetic associations. With the ongoing 316 expansion of GWAS interpretation, the effective integration of LSS and GRPS will

317 offer further opportunities and possibilities for disease prediction, treatment and

318 prevention.

319

320 References

321	1.	M. Dehlin, L. Jacobsson, E. Roddy, Global epidemiology of gout: prevalence,
322		incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16, 380-390
323		(2020).
324	2.	C. Ponticelli, M. A. Podesta, G. Moroni, Hyperuricemia as a trigger of
325		immune response in hypertension and chronic kidney disease. <i>Kidney Int</i> 98,
326		1149-1159 (2020).
327	3.	X. Li et al., Serum uric acid levels and multiple health outcomes: umbrella
328		review of evidence from observational studies, randomised controlled trials,
329		and Mendelian randomisation studies. BMJ 357, j2376 (2017).
330	4.	T. J. Major, R. K. Topless, N. Dalbeth, T. R. Merriman, Evaluation of the diet
331		wide contribution to serum urate levels: meta-analysis of population based
332		cohorts. BMJ 363, k3951 (2018).
333	5.	J. S. Park, Y. Kim, J. Kang, Genome-wide meta-analysis revealed several
334		genetic loci associated with serum uric acid levels in Korean population: an
335		analysis of Korea Biobank data. J Hum Genet 67, 231-237 (2022).
336	6.	N. Dalbeth, A. L. Gosling, A. Gaffo, A. Abhishek, Gout. Lancet 397, 1843-
337		1855 (2021).
338	7.	A. Tin et al., Target genes, variants, tissues and transcriptional pathways
339		influencing human serum urate levels. Nat Genet 51, 1459-+ (2019).
340	8.	A. Kottgen et al., Genome-wide association analyses identify 18 new loci
341		associated with serum urate concentrations. Nat Genet 45, 145-154 (2013).
342	9.	K. Watanabe, E. Taskesen, A. van Bochoven, D. Posthuma, Functional
343		mapping and annotation of genetic associations with FUMA. Nat Commun 8,
344		1826 (2017).
345	10.	H. Lango Allen et al., Hundreds of variants clustered in genomic loci and
346		biological pathways affect human height. Nature 467, 832-838 (2010).
347	11.	M. J. Flister <i>et al.</i> , Identifying multiple causative genes at a single GWAS
348		locus. Genome Research 23, 1996-2002 (2013).
349	12.	C. C. Chung et al., Fine mapping of a region of chromosome 11q13 reveals
350		multiple independent loci associated with risk of prostate cancer. Hum Mol
351		<i>Genet</i> 20 , 2869-2878 (2011).
352	13.	A. Tin et al., Epigenome-wide association study of serum urate reveals
353		insights into urate co-regulation and the SLC2A9 locus. Nature
354		Communications 12, (2021).

355	14.	M. Song et al., Mapping cis-regulatory chromatin contacts in neural cells links
356		neuropsychiatric disorder risk variants to target genes. Nat Genet 51, 1252-
357		1262 (2019).
358	15.	K. K. Farh et al., Genetic and epigenetic fine mapping of causal autoimmune
359		disease variants. Nature 518, 337-343 (2015).
360	16.	G. Kichaev et al., Integrating functional data to prioritize causal variants in
361		statistical fine-mapping studies. PLoS Genet 10, e1004722 (2014).
362	17.	C. Giambartolomei et al., Bayesian Test for Colocalisation between Pairs of
363		Genetic Association Studies Using Summary Statistics. Plos Genetics 10,
364		(2014).
365	18.	J. C. Ulirsch et al., Interrogation of human hematopoiesis at single-cell and
366		single-variant resolution. Nat Genet 51, 683-+ (2019).
367	19.	K. J. Gaulton, S. Preissl, B. Ren, Interpreting non-coding disease-associated
368		human variants using single-cell epigenomics. Nat Rev Genet 24, 516-534
369		(2023).
370	20.	N. Dalbeth et al., Gout. Nat Rev Dis Primers 5, 69 (2019).
371	21.	E. A. King, J. W. Davis, J. F. Degner, Are drug targets with genetic support
372		twice as likely to be approved? Revised estimates of the impact of genetic
373		support for drug mechanisms on the probability of drug approval. Plos Genet
374		15 , (2019).
375	22.	M. R. Nelson et al., The support of human genetic evidence for approved drug
376		indications. Nat Genet 47, 856-860 (2015).
377	23.	A. K. Wong, R. S. G. Sealfon, C. L. Theesfeld, O. G. Troyanskaya, Decoding
378		disease: from genomes to networks to phenotypes. Nat Rev Genet 22, 774-790
379		(2021).
380	24.	J. A. Morris et al., Discovery of target genes and pathways at GWAS loci by
381		pooled single-cell CRISPR screens. Science 380, 705-+ (2023).
382	25.	V. Tam et al., Benefits and limitations of genome-wide association studies.
383		Nat Rev Genet 20, 467-484 (2019).
384	26.	J. Nasser et al., Genome-wide enhancer maps link risk variants to disease
385		genes. Nature 593, 238-243 (2021).
386	27.	E. Mountjoy et al., An open approach to systematically prioritize causal
387		variants and genes at all published human GWAS trait-associated loci. Nat
388		<i>Genet</i> 53 , 1527-+ (2021).
389	28.	N. Y. A. Sey et al., A computational tool (H-MAGMA) for improved
390		prediction of brain-disorder risk genes by incorporating brain chromatin
391		interaction profiles. Nat Neurosci 23, 583-593 (2020).
392	29.	P. W. Hook, A. S. McCallion, Leveraging mouse chromatin data for
393		heritability enrichment informs common disease architecture and reveals
394		cortical layer contributions to schizophrenia. Genome Res 30, 528-539 (2020).
395	30.	K. Zhang et al., A single-cell atlas of chromatin accessibility in the human
396		genome. Cell 184, 5985-6001 e5919 (2021).

397	31.	C. A. Boix, B. T. James, Y. P. Park, W. Meuleman, M. Kellis, Regulatory
398		genomic circuitry of human disease loci by integrative epigenomics. Nature
399		590 , 300-307 (2021).
400	32.	D. Diogo et al., Phenome-wide association studies across large population
401		cohorts support drug target validation. Nat Commun 9, 4285 (2018).
402	33.	G. H. Kim, J. B. Jun, Altered Serum Uric Acid Levels in Kidney Disorders.
403		<i>Life (Basel)</i> 12 , (2022).
404	34.	K. Trajanoska et al., From target discovery to clinical drug development with
405		human genetics. Nature 620, 737-745 (2023).
406	35.	Z. A. Zhao et al., CDER167, a dual inhibitor of URAT1 and GLUT9, is a
407		novel and potent uricosuric candidate for the treatment of hyperuricemia (vol
408		43, pg 121, 2022). Acta Pharmacol Sin 43, 1884-1884 (2022).
409	36.	R. Bao et al., Eurycomanol alleviates hyperuricemia by promoting uric acid
410		excretion and reducing purine synthesis. Phytomedicine 96, 153850 (2022).
411	37.	S. Konermann et al., Genome-scale transcriptional activation by an engineered
412		CRISPR-Cas9 complex. Nature 517, 583-588 (2015).
413	38.	V. F. Azevedo, I. A. Kos, A. B. Vargas-Santos, G. da Rocha Castelar Pinheiro,
414		E. dos Santos Paiva, Benzbromarone in the treatment of gout. Advances in
415		Rheumatology 59 , 37 (2019).
416	39.	Q. Wang et al., Single-cell chromatin accessibility landscape in kidney
417		identifies additional cell-of-origin in heterogenous papillary renal cell
418		carcinoma. Nat Commun 13, 31 (2022).
419	40.	P. C. Wilson et al., The single-cell transcriptomic landscape of early human
420		diabetic nephropathy. Proc Natl Acad Sci USA 116, 19619-19625 (2019).

421

422 Acknowledgments

Funding: J.Y. is grateful to support from The Open Project of Jiangsu Provincial
Science and Technology Resources (Clinical Resources) Coordination Service
Platform JSRB2021-01. S. S. is grateful to support from National Natural Science
Foundation of China (82170723).

427 Author Contributions: J.Y. conceived of and designed the project. J.Z., Y.G., and L.G.
428 performed research. J.Z., L.X., Q.L., K.W., and Q.W. contributed to data analysis. J.Y.,
429 J.Z., S.S., and Z.Q. wrote the manuscript with input from all authors. All authors read
430 and approved the final submission of the manuscript.

431 **Conflict of interests:** The authors declare that they have no competing interests.

Data and materials availability: The kidney scATAC-seq publicly available data used 432 433 in this study are available in the Gene Expression Omnibus (GEO) under GSE166547 (39). The kidney scRNA-seq data used in this study are publicly available in the GEO 434 435 under GSE131882 (40). Kidney tubule eQTL derives from NephQTL browser (https://www.nephqtl.org). Epigenomic profiles from EpiMap is available at 436 http://compbio.mit.edu/epimap/. Main code used in processing and analysis of the 437 438 data in this article is available at https://github.com/NJU-labyang/hyperuricemia. Any code not provided there will be made available upon request. 439



Fig. 1 Locus-specific stratification leverages interpretability of loci with multipleindependent-associations. (A) Number of loci with single or multiple independent

444 associations in three serum urate GWAS studies, respectively. (B and C) LocusZoom 445 plot (B) and quantile-quantile plot (C) for GWAS result at locus chr4:9,743,616-10,243,616 with lead SNP rs3775947. (D) Overview of the LSS strategy. The variants 446 447 were ranked by descending significance of variant-trait associations within each locus, and candidate high-risk variants defined as those in the top quartile. High-risk variants 448 449 were further integrated with kidney scATAC-seq data to identify functional high-risk 450 variants. (E and F) Quantile-quantile plots for GWAS result at locus with multiple 451 independent associations (E) or single association (F). The lead SNP and independent 452 (LD R²<0.8) high-risk (Rank1) SNPs were highlighted. (G) Percentage of interpretable 453 loci for GWAS of serum urate (EA Tin). Four strategies including LSS, LD extension 454 of lead SNP, Bayesian fine-mapping and kidney colocalization were used. (H) Odds 455 ratios of genetic contribution for functional high-risk variants identified by four 456 strategies. eGFRcrea, creatinine-based estimated glomerular filtration rate; BUN, blood 457 urea nitrogen; CKD, chronic kidney disease; LM, leptin measurement; CD, Crohn's 458 disease; MS, multiple sclerosis.



Fig. 2 LSS reveals cell-type-dependent functional variants of hyperuricemia. (A)
Number of high-risk variants overlapping with regulatory elements in each cell type of
the kidney, including proximal convoluted tubule (PCT), collecting duct alpha
intercalated cells (CDICA), distal convoluted tubule (DCT), collecting duct principal
cell (CDPC), loop of Henle (LOH), endothelium (ENDO), podocyte (PODO), parietal
epithelial cells (PEC), and mesangial cell (MES). (B) Proportion of functional high-risk

466 variants that exert their function in unique cell types, 2-3 cell types, and multiple cell types in kidney. (C) LocusZoom plot of GWAS result in locus chr8:75,316,533-467 75,816,533 with lead SNP rs2941484 (top) and genome browser view for the 468 469 highlighted region (bottom). The genome browser tracks include chromatin 470 accessibilities in cell types from kidney scATAC-seq, the position of the lead SNP, 471 proxy SNP (LD extension of lead SNP) and functional high-risk SNP. (D) The 472 PheWAS results for rs2943549 with colors representing significantly associated 473 diseases and traits (p<0.05). (E) LocusZoom plot and genome browser view for locus chr4:9,743,616-10,243,616 with lead SNP rs3775947 as (C). (F) The PheWAS results 474 475 for rs4447862 as (D).



477

Fig. 3 Regulatory network elucidates the regulatory mechanism for target genes and functional variants in hyperuricemia. (A) Overview of the construction of transcriptional regulatory networks of kidney cell types by computing the correlation between chromatin accessibility and gene expression. (B) Percentage of loci with

482 kidney candidate causal genes identified in GWAS of serum urate (EA Tin). (C) 483 Number of candidate causal genes identified by different strategies. (D and E) Top 5 484 diseases enriched for the candidate causal genes identified with all LSS high-risk 485 variants (D) or LSS-only high-risk variants (E). (F) LocusZoom plot of GWAS result in locus chr1:154,935,239-155,435,239 with the lead SNP rs2070803 (top), and 486 487 genome browser view of the highlighted region (bottom). The genome browser includes 488 overlaid track of chromatin accessibilities in kidney cell types, the tracks for chromatin accessibilities in DCT or CDPC, the tracks for location of the lead SNP, proxy SNP and 489490 functional high-risk SNP, the track for gene location, and the track for the peak-to-gene 491 linkage. rs3814316-harboring-CRE and MUC1 promoter are marked with orange and 492 yellow boxes, respectively. (G) CADD scores for lead SNP, proxy SNPs and functional 493 high-risk SNP. (H) Significance and effect size of the relationship between genotypes 494 of variants and MUC1 expression in kidney tubule eQTL.



Fig. 4 GRPS determines the priority of candidate risk genes. (A) Percentage of functional high-risk variants that can regulate 1 or more genes. (B) Percentage of gene that can be regulated by 1 or more functional high-risk variants. (C) Overview of GRPS strategy. For each gene, a regulatory prioritization score is calculated based on cumulative regulations (Methods). (D) Percentage of genes supported by prior evidence. Genes are divided into 4 groups based on GRPS from highest to lowest. (E) Top 25% genes ranked by the GRPS prioritization with their annotation as putative drug targets,

- 504 urate transporter, and disease association by DISEASE displayed. (F and G) The
- 505 performance of four different prioritizing methods in predicting the probability (**F**) and
- 506 odds ratio (G) of putative drug targets, which was evaluated by logistic regression.



508

Fig. 5 *SLC17A4* is regulated by high-risk variant and promotes the transport of
uric acid. (A) LocusZoom plot of GWAS result in locus chr6:25,559,488-26,059,488
with lead SNP rs1359232 (top), and genome browser view of the highlighted region
(bottom). The genome browser includes tracks for chromatin accessibilities in kidney

513 cell types, the position of the lead SNP and functional high-risk SNP, the location of 514 sgRNA designed for CRISPRa experiment, the location of genes, and the peak-to-gene 515 linkage. rs1165183-harboring-CRE and SLC17A4 promoter are marked with orange 516 and yellow boxes, respectively. (B) Gene expression of SLC17A4 in kidney cell types. (C) SLC17A4 expression determined by qPCR in CRISPRa HEK293T lines treated 517 518 with non-targeting negative sgRNA or rs1165183-harboring-CRE sgRNA (CRE 519 sgRNA) (n=3, two-tailed Student's t test, P-value for cells treated with negative sgRNA 520 vs CRE sgRNA is 0.005, * indicates P-value <0.05). (D) SLC17A4 expression in 521 HEK293T cells treated with negative control plasmid and SLC17A4 overexpression 522 (OE) plasmid (n=3, two-tailed Student's t test, P-value for cells treated with negative control plasmid vs SLC17A4 OE plasmid is 0.0006, * indicates P-value <0.05). (E) 523 524 Effects of SLC17A4 overexpression (OE) on the intracellular urate levels of HEK293T 525 cells (n=3, two-tailed Student's t test, P-value for negative control cells which are 526 untreated or treated with uric acid (UA) is 0.0012; P-value for negative control vs 527 SLC17A4 OE cells which are all treated with UA is 0.0033, P-value for negative control 528 cells vs SLC17A4 OE cells which are all untreated with UA is 0.5185, P-value for 529 SLC17A4 OE cells which are untreated or treated with UA is 0.0351; * indicates P-530 value <0.05, NS indicates not significant).